<unk>  is indicated for the treatment of secondary progressive multiple sclerosis (SPMS), which is the progressive neurological decline of multiple sclerosis that happens independent of acute relapses. In active SPMS,<unk>  decreases the risk of disability and MS relapses.
Siponimod
Ozanimod
Ponesimod
Calaspargase pegol
Belinostat
Inotersen
Nusinersen
Vosoritide